Study of Troriluzole Treatment Around Surgery for Recurrent IDH Wild-Type Glioblastoma

What this Trial Is About

Researchers are studying troriluzole as a potential treatment for people with recurrent isocitrate dehydrogenase wild-type IDH WT glioblastoma, a type of brain tumor. This is an open-label, randomized early phase clinical trial designed as a surgical window-of-opportunity study to see how active troriluzole is on tumors. The study is funded by Biohaven Pharmaceuticals and involves about 27 participants who have surgically accessible tumors. Participants are randomly assigned in a 21 ratio to one of two groups. Group A receives troriluzole twice daily for six days before surgery, followed by surgery and continued troriluzole treatment in 28-day cycles. Group B undergoes surgery first without pre-surgery troriluzole, then starts the same post-surgery troriluzole treatment. Both groups have MRI scans before and after surgery and every eight weeks during treatment, with follow-up visits every three months for one year and then every six months for three more years. Participants will have screening evaluations, blood tests, tumor biopsies, MRI scans, and electrocardiograms ECGs throughout the study. Researchers will measure the effect of troriluzole on brain activity during surgery using electrocorticography and analyze tumor tissue for various biological markers. Safety will be monitored closely, and the total participation may last several years due to the extended follow-up schedule.

A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma